Randomized, Double-masked, Parallel-group, Phase 1 Study, to Compare CMAB807 Injection to Prolia ® in Healthy Volunteers
Condition: Postmenopausal Osteoporosis Interventions: Drug: Prolia®; Drug: CMAB807 Sponsor: Shanghai Biomabs Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials